FDA approves Eli Lilly’s tirzepatide for obesity, paving way for even wider use of blockbuster drug
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VNXSQGH2GVPD5PRDVOKIA7MC6E.jpg "Budget crisis looms on day one for Sweden’s first female PM")